How deep does the
treatment need to go?

Neither is universally better. ULTRA and CO₂ belong to different resurfacing-intensity conversations. ULTRA — the LaseMD Ultra, a 1927 nm non-ablative fractional thulium laser made by Cynosure Lutronic — uses a fractional laser approach that treats a pattern of microzones while leaving intervening tissue intact. CO₂ laser technology uses approximately 10,600 nm infrared energy that is strongly absorbed by water in tissue; it is an ablative resurfacing technology, and when delivered fractionally it creates microscopic columns of ablation while leaving untreated skin between them. The appropriate choice depends on what we are treating, how deep the concern sits, how much change is needed, how much recovery is acceptable, and the patient's skin and pigment risk profile.

For patients in Dallas, Highland Park, University Park, the Park Cities, and Preston Hollow comparing ULTRA vs. CO₂ laser, the more useful question is never which laser is stronger. It is how much resurfacing this skin actually needs.

ULTRA — also marketed as LaseMD Ultra — is a non-ablative fractional thulium laser manufactured by Cynosure Lutronic. It delivers 1927 nm energy in a fractional pattern, creating treated microzones surrounded by untreated skin that supports recovery. The wavelength has a strong affinity for water in tissue, and the platform uses a 200 μm microbeam with magnetic roller tracking (IntelliTrak) and Controlled Chaos Technology to help keep energy delivery consistent.

ULTRA's FDA-cleared indications include the coagulation of soft tissue, treatment of actinic keratosis, and treatment of benign pigmented lesions such as lentigos, solar lentigos, and ephelides. In practice it is used for a broader set of skin-quality concerns — texture, tone, sun-related pigment, fine lines, and post-acne marks — within its cleared indications. For the complete specification-led overview, read the Complete ULTRA Guide.

A CO₂ laser uses approximately 10,600 nm infrared light. At that wavelength, water in tissue is a major chromophore — the energy is strongly absorbed by water-containing tissue. This allows CO₂ energy to vaporize or ablate tissue depending on the device and settings used. The result is a controlled removal of tissue, which is why CO₂ belongs to the ablative resurfacing category.

CO₂ laser resurfacing has a long clinical history in dermatology and dermatologic surgery. It has been used for photodamage, fine and deeper lines, certain acne scars, and broader resurfacing goals. CO₂ can be delivered in a full-field pattern — treating the entire surface — or fractionally, creating microscopic columns of ablation with intervening untreated tissue. Not every CO₂ treatment is identical: the device, the pattern, the density, and the settings all shape what the treatment actually is.

This is why comparing ULTRA vs. CO₂ as a simple weak-versus-strong question is medically simplistic. They differ in wavelength, tissue interaction, ablation status, intensity, recovery, and treatment goal.

CO₂ IS NOT SIMPLY A STRONGER VERSION OF ULTRA. IT IS A DIFFERENT RESURFACING CATEGORY.

Ablative resurfacing intentionally removes or vaporizes portions of skin tissue. The controlled removal of tissue is what creates a more intensive resurfacing effect — and it is also what creates a more intensive healing response. The skin needs to re-epithelialize, meaning new surface tissue must form over the treated area.

This is not inherently dangerous or extreme. It is a deliberate mechanism with a long clinical track record. But it does mean the recovery conversation is different from a non-ablative treatment. More intensive ablation can create more visible redness, more peeling, a longer healing window, and a different aftercare commitment.

The clinical question is whether the concern being treated warrants that level of tissue removal. Ablation is a tool, not a verdict.

Non-ablative laser treatment heats or treats targeted tissue without intentionally vaporizing the epidermal surface in the way an ablative laser does. ULTRA is classified as a non-ablative fractional laser: it creates thermal microzones that stimulate a skin-revitalization response while leaving surrounding tissue intact. Some materials describe its effect as sub-ablative, meaning it is near the boundary but is not a full ablative resurfacing device.

The practical result is generally less visible downtime than ablative resurfacing, and improvement is often built cumulatively over a series rather than in a single intensive session. Non-ablative does not mean no treatment — it means a different tissue interaction and a different recovery profile.

ULTRA sits in the non-ablative fractional category. That classification shapes downtime, candidacy, and how many sessions may be part of a plan.

Fractional describes how treatment is distributed, not what the treatment does to tissue. A fractional laser treats a fraction of the surface — a pattern of microscopic treatment zones — while leaving intervening skin untreated. That untreated tissue serves as a reservoir for healing.

Critically, fractional does not tell you whether a treatment is ablative. A treatment can be fractional and non-ablative, or it can be fractional and ablative. These are two different properties.

Fractional CO₂ delivers ablative treatment in microscopic columns. Each column vaporizes tissue; the skin between columns is left untreated to support healing. This is different from full-field CO₂, which treats the entire surface in one pass.

Fractional CO₂ is still ablative. The fractional pattern reduces recovery compared to full-field CO₂, but it does not make the treatment non-ablative. The tissue in each treated column is still vaporized.

This is one of the most important distinctions in laser resurfacing: fractional CO₂ is fractional and ablative. ULTRA is fractional and non-ablative. They share a delivery pattern but not a tissue effect.

No. This is marketing shorthand, and it is medically inaccurate. ULTRA should not be described as CO₂ without the downtime because the two technologies differ in wavelength, tissue interaction, ablation status, intensity, and treatment goal.

ULTRA uses 1927 nm thulium energy delivered fractionally and non-ablatively. CO₂ uses approximately 10,600 nm energy that ablates tissue. They are not the same laser at different intensities. They are different resurfacing categories.

The appropriate endpoint for ULTRA should be based on what ULTRA is designed to do — not on trying to make it impersonate CO₂. A different treatment should be allowed to be different.

Resurfacing technologies exist across a spectrum, from lower visible recovery to greater visible recovery. No single device sits at a fixed point on this spectrum — settings, density, and protocol all move a treatment along it. But the categories are useful for understanding why intensity should follow indication.

This is conceptual, not a fixed ranking. A specific device at specific settings may move along this spectrum. The point is that recovery is part of the prescription, not an afterthought.

The table below compares the verified specifications of ULTRA with the established properties of CO₂ laser technology. Only verified information is included. Where a property is device- or protocol-dependent, that is noted.

ULTRA's 1927 nm thulium wavelength has a specific relationship with tissue — a high affinity for water in the superficial layers. CO₂ at approximately 10,600 nm is also strongly absorbed by water, but the tissue interaction is different because the energy vaporizes rather than coagulates.

This means ULTRA and CO₂ should not be compared only by an energy number, by heat, or by a vague sense of strength. Two lasers that both interact with water can produce very different effects depending on wavelength, delivery pattern, and whether the mechanism is ablative or non-ablative.

The wavelength is the foundation of the tissue interaction. Everything else — depth, intensity, recovery, risk — follows from it.

Different concerns occupy different levels of the skin. A surface brown spot, a textural irregularity, a fine line, and a deep acne scar do not live at the same depth — and they do not all require the same intensity of treatment. The diagram below is conceptual, not a universal device-depth prescription.

Matching the depth of treatment to the depth of the concern is the core of prescription-led resurfacing. Going deeper than the problem requires does not automatically create a better outcome.

Going deeper than the problem requires may increase recovery, risk, and inflammation without necessarily creating a better result. A surface pigment concern does not need dermal-depth ablation. A mild texture irregularity does not need the recovery profile of full-field resurfacing.

This is a central JOLA principle: more aggressive is not automatically more appropriate, and less downtime is not automatically better. The treatment should match the concern, the depth, the skin, the risk profile, the recovery tolerance, and the desired magnitude of change.

This is the framework JOLA uses for every resurfacing conversation: depth, intensity, skin, recovery, result. The device comes after the depth — not before.

Texture concerns — roughness, surface irregularity, photoaging-related fine texture, post-acne texture — span a range of depths and severities. Treatment intensity should correspond to the magnitude of the concern. Mild to moderate texture may respond well to a non-ablative fractional approach; more pronounced textural change may warrant a more intensive resurfacing conversation.

ULTRA's 1927 nm fractional delivery is designed to improve surface quality and tone with lower downtime, built cumulatively over a series. CO₂ resurfacing, being ablative, creates a more intensive surface renewal — but with a more intensive recovery. Neither is automatically correct for texture; the choice depends on how significant the texture is and how much recovery is acceptable.

For the full texture and pores conversation, read the ULTRA Texture + Pores guide.

Neither ULTRA nor CO₂ permanently removes pores. Pores are normal anatomy. Pore appearance may relate to oil production, genetics, elasticity, photoaging, texture, and acne history. Resurfacing can improve the appearance of pores by improving surrounding skin quality — but it does not eliminate them.

A non-ablative fractional approach like ULTRA may refine pore appearance over a series with lower downtime. A more intensive ablative approach may create more visible surface renewal, but the recovery and risk profile are different. The question is not which laser shrinks pores — neither does — but how much surrounding-skin improvement is appropriate for the concern.

For the full pore conversation, read the ULTRA Texture + Pores guide.

Acne marks are not scars. They are color — brown marks (post-inflammatory hyperpigmentation) or red marks (post-inflammatory erythema) left after a breakout resolves. The distinction matters because color does not require the same intensity of treatment as structural change.

CO₂ intensity is not automatically appropriate for color alone. Ablative resurfacing for a brown mark may introduce more recovery and pigment risk than the concern warrants. ULTRA's non-ablative fractional approach may be considered for selected pigment-related marks.

For the full marks-versus-scars conversation, read the ULTRA Acne Marks + Scars guide.

Acne scars involve structural change in the skin. Scar morphology — rolling, boxcar, ice-pick, tethered, or mixed — determines what kind of treatment makes sense. A deeper or more aggressive resurfacing approach may sometimes be considered for structural scarring, but device selection depends on the scar type and the patient.

ULTRA's non-ablative fractional approach may be considered for selected post-acne texture and superficial concerns. More intensive ablative resurfacing may be considered for certain scarring where the morphology and depth warrant it. But no single laser is correct for every scar.

For scar-specific planning, read the ULTRA Acne Marks + Scars guide.

No. Deep acne scars may require scar-specific approaches rather than resurfacing alone. Subcision, TCA CROSS, filler, or combination protocols may be more appropriate depending on the scar type. A more aggressive laser does not solve a scar that needs a different mechanism.

Ice-pick scars, for example, are narrow and deep — resurfacing the surface does not address the channel. Tethered rolling scars may need release before any resurfacing is meaningful. The scar morphology determines the approach, not the other way around.

This is why a consultation matters before any device is selected. The question is not which laser is strongest, but which mechanism fits this scar.

Conceptually, a more intensive resurfacing treatment may deserve consideration when the concern is significant: advanced photodamage, more pronounced etched lines, certain scar patterns, or more advanced texture concerns where a greater magnitude of change is the goal and the recovery is acceptable.

This is not a remote prescription. Whether a more intensive ablative approach is appropriate depends on the individual, the skin, the pigment risk, the scar morphology, and the recovery tolerance. JOLA does not prescribe intensity without a consultation.

The point is that more intensive resurfacing is a tool — selected when the concern warrants it, not chosen by default.

A lower-downtime approach may make more sense for milder concerns, for maintenance, for patients who prioritize recovery, for incremental improvement, and for certain pigment or texture goals where a series of lower-intensity sessions is clinically appropriate.

Less downtime does not mean less effective. It means a different intensity, often built cumulatively. ULTRA's non-ablative fractional approach is designed for this kind of plan — real treatment, real skin response, lower visible recovery.

The goal is the right amount of treatment, not the most or the least.

Fine etched lines — the surface lines related to photoaging and collagen change — may respond to resurfacing. Dynamic lines, the lines created by repeated movement, respond to neuromodulators, not lasers. Deeper folds involve volume and structural change that a laser alone may not address.

ULTRA may be considered for fine surface lines within a lower-downtime series. More intensive ablative resurfacing may be considered for more pronounced lines. But laser resurfacing does not replace neuromodulators when movement is the primary cause of a line.

For the neuromodulator conversation, read the JOLA injectables guide.

Deeper wrinkles may involve dermal change, movement, volume loss, and structural aging. A laser alone may not address every component. Resurfacing can improve the surface quality of a wrinkle, but it does not replace volume restoration or movement management where those are the primary drivers.

This is why a wrinkle is not a single problem. A deep nasolabial fold, a dynamic forehead line, and an etched perioral line each have different causes and different appropriate responses. Comparing ULTRA vs. CO₂ for deep wrinkles without identifying the type of wrinkle is incomplete.

The consultation identifies what is creating the wrinkle before any laser is selected.

Perioral lines — the vertical lines around the mouth — involve movement, skin thickness, etched lines, and volume changes. The mouth moves constantly, which is why these lines are among the most stubborn. Laser resurfacing can improve the surface quality of perioral lines, but it does not promise eradication.

A lower-downtime fractional approach may refine perioral texture over a series. A more intensive ablative approach may create more visible surface renewal. But movement continues, and volume changes may need to be addressed separately. No laser stops the mouth from moving.

The honest expectation is improvement, not elimination.

The eye area involves fine lines, crepey texture, laxity, dynamic movement, and anatomical sensitivity. Not every device is appropriate for eyelid skin. Treatment-area information must be verified — the skin around the eyes is thinner and more reactive than facial skin.

ULTRA's treatment areas should be confirmed against current manufacturer documentation. CO₂ resurfacing around the eyes requires particular care and appropriate settings. The consultation determines what is appropriate for this area, not a general assumption.

Do not assume every laser is appropriate for every area. The eye area demands specific, verified treatment planning.

Sun damage is not one condition. It may include pigmentation, texture change, fine lines, elasticity changes, and vascular changes. The right resurfacing approach depends on what the sun damage actually looks like and how significant it is.

ULTRA may be considered for selected sun-damage concerns — sun spots, freckles, tone, and early photoaging — within its cleared indications. More intensive ablative resurfacing may be considered for more advanced photodamage. Neither treats every manifestation of sun damage.

For the full sun-damage conversation, read the ULTRA Sun Damage guide.

Ablative intensity is not automatically necessary for brown pigment. A sun spot, a post-acne mark, and melasma are different processes, and diagnosis matters before a device is selected. ULTRA's FDA-cleared indications include benign pigmented lesions such as lentigos, solar lentigos, and ephelides.

For many brown spots within cleared indications, a lower-downtime fractional approach may be appropriate. More intensive ablation introduces more recovery and pigment risk, which may not be warranted for a surface lesion. The diagnosis determines the device, not the other way around.

For the full pigmentation conversation, read the ULTRA Pigmentation guide.

Neither ULTRA nor CO₂ should be presented as a universal cure for melasma. Melasma is complex and recurrent, influenced by heat, inflammation, UV exposure, visible light, and hormones. Laser energy creates heat and inflammation, which can worsen melasma in some patients.

Any resurfacing for melasma must be considered carefully within a broader management plan that includes sun protection, topical management, and an understanding of triggers. More intensive resurfacing does not automatically mean better pigment control — it may mean more inflammation and more risk of rebound or post-inflammatory hyperpigmentation.

Richer skin tones have more melanin, which means a higher baseline risk of post-inflammatory hyperpigmentation after any energy-based treatment. Both ULTRA and CO₂ require thoughtful settings, appropriate intensity, and provider experience for darker skin. Neither should be declared universally safe or unsafe.

The consultation evaluates skin tone, pigment history, PIH risk, and previous treatments before any device is selected. Settings are adjusted — not copied from a lighter skin tone. More intensive ablation generally carries higher pigment risk, which is why CO₂ requires particularly thoughtful patient selection for richer skin.

This is not about excluding patients. It is about prescribing intensity that respects how this skin heals.

More intensive ablation means more tissue removal, more healing, and a different pigment, infection, erythema, and scarring risk profile depending on the patient and protocol. CO₂ is not unsafe — it is a well-established technology with a long clinical track record — but it requires appropriate selection and aftercare.

The factors that matter: skin tone, pigment history, previous treatments, barrier health, sun exposure, downtime tolerance, and the specific concern being treated. A patient who heals well and has an appropriate concern may do very well. A patient with higher pigment risk or a concern that does not warrant ablation may not be the right candidate.

This is why CO₂ is never selected remotely. It is selected in consultation, after the skin and history have been assessed.

A history of post-inflammatory hyperpigmentation materially changes resurfacing planning. If you have darkened after acne, after a previous laser, after a chemical peel, after a burn, after irritation, after previous CO₂, or after previous microneedling, that history tells us how your skin tends to respond to inflammation.

This does not automatically disqualify you from resurfacing. It means the intensity, the settings, and the plan must account for that tendency. A lower-downtime approach with conservative settings may be appropriate where a more intensive ablative approach may not be.

PIH history is one of the most important variables in resurfacing planning. It is assessed at consultation, not assumed.

Yes. Any laser that delivers energy creates a controlled injury, and skin that tends to darken after inflammation may develop PIH. No laser should be marketed as zero-risk. ULTRA's non-ablative fractional approach is generally associated with lower pigment risk than ablative resurfacing, but lower risk is not no risk.

PIH risk is assessed during consultation and factored into the treatment plan — settings, intensity, treatment area, and aftercare all account for how this skin tends to respond.

Yes. CO₂ resurfacing is known to carry a risk of post-inflammatory hyperpigmentation, particularly in richer skin tones and with more intensive ablation. The risk is higher than with non-ablative fractional resurfacing because the tissue interaction is more intensive.

This is not a reason to fear CO₂. It is a reason to select it thoughtfully. The pigment risk is part of the consultation, and it is one of the factors that determines whether ablative resurfacing is appropriate for a given patient.

Hypopigmentation — a loss of pigment — is a recognized risk with more intensive ablative resurfacing. It is more associated with deeper, more aggressive treatment. The exact incidence depends on the device, settings, skin tone, and individual.

We do not invent incidence rates. The point is that pigment change, in either direction, is a known consideration with ablative resurfacing, and it is part of why patient selection matters.

Any procedure that creates controlled injury carries some risk of scarring. More intensive ablative procedures require appropriate patient selection and aftercare to manage that risk. This is not a reason to avoid resurfacing — it is a reason to have it performed by an experienced provider with a clear aftercare plan.

The risk is managed through selection, settings, technique, and aftercare. It is not eliminated, and no responsible provider promises zero risk. The consultation includes an honest discussion of what the recovery and risk profile look like for the specific treatment being considered.

There is no universal answer. Sensation depends on the device, settings, treatment area, numbing protocol, and individual sensitivity. CO₂ resurfacing protocols can require more intensive anesthesia or comfort management depending on the extent of treatment. ULTRA comfort depends on the actual settings and JOLA protocol.

Both are generally manageable with appropriate numbing. The difference is that more intensive ablation may require more intensive comfort management — but that is determined by the treatment plan, not by a universal pain ranking.

Comfort management is not one thing. Topical numbing, local anesthesia, nerve blocks, sedation, and other comfort protocols may be used differently depending on the procedure. Not every CO₂ treatment requires sedation — that depends on the extent, the area, and the protocol.

Do not assume every CO₂ treatment requires sedation. Do not assume every ULTRA treatment is painless. Comfort is part of the treatment plan, discussed at consultation.

This is one of the most important commercial sections in this comparison. Downtime is not a single number for either technology. ULTRA's non-ablative fractional approach is generally associated with lower visible recovery — redness, mild swelling, dryness, and flaking — built over a series. CO₂ resurfacing, being ablative, involves more visible healing — more significant redness, swelling, oozing or crusting where relevant to ablative treatment, peeling, and a longer visible recovery window.

The specifics depend on settings, density, treatment area, and individual response. We do not create exact timelines unless well supported. What we can say is that ablation changes the recovery conversation: the skin must re-epithelialize, which is a different biological process from the thermal response of a non-ablative treatment.

For the full recovery conversation, read the ULTRA Downtime + Recovery guide.

Downtime is more than redness. It is a set of practical questions about what you can and cannot do while healing. The honest answer depends on the treatment, the settings, and the type of life you lead.

Remote work, office work, client-facing work, and on-camera work are different questions. A dinner with friends and a professional photoshoot are different questions. Downtime is contextual, and it is part of the consultation conversation.

Healing is biologic recovery — the time the skin takes to re-epithelialize, settle, and remodel. Social downtime is how comfortable someone feels being seen during that process. They are not identical.

A patient may be biologically healed but still feel socially not ready, or vice versa. Both matter, and both are part of the planning conversation.

ULTRA recovery depends on the settings, treatment area, and individual response. JOLA's protocol is designed for lower visible downtime than ablative resurfacing, with recovery managed through specific aftercare. The exact timeline is part of the consultation, based on the specific plan.

For the full recovery and aftercare conversation, read the ULTRA Downtime + Recovery guide.

CO₂ recovery varies significantly based on whether the treatment is fractional or full-field, the density, the energy, the treatment area, the individual, the aftercare, and the device. There is no one universal number. Fractional CO₂ generally involves less recovery than full-field CO₂, but both are ablative and both require re-epithelialization.

This is why CO₂ recovery is always discussed in the context of the specific plan. A generic number is not responsible.

After the initial re-epithelialization — when the surface has closed — some patients experience persistent erythema, a lingering redness that can extend beyond the initial healing window. This is a known phenomenon with ablative resurfacing and is related to the skin's continued vascular response during remodeling.

This is not a complication to fear. It is a part of the recovery profile that should be understood before treatment, so the timeline is realistic. Persistent erythema is one reason social downtime and biologic healing are not the same thing.

Treatment intensity changes planning. A major event is not the time to discover an unknown recovery pattern. Whether ULTRA or a more intensive approach is appropriate before an event depends on the timing, the intensity, the number of sessions, and your expected response.

The calendar is built in advance — not by scheduling a treatment close to the date and hoping. The consultation includes event timing as part of the plan.

A wedding requires a treatment calendar built months in advance. We do not prescribe arbitrary treatment dates. The plan considers series planning, skin response, recovery buffer, maintenance, and sun protection. Neither ULTRA nor CO₂ should be scheduled close to a wedding without adequate margin.

A lower-downtime series may be appropriate for a wedding timeline. A more intensive ablative treatment may be appropriate if scheduled far enough in advance. The choice depends on the concern, the skin, and the timeline — and on leaving room for the skin to settle.

Intensive resurfacing and a sunny vacation may require particularly thoughtful scheduling. Freshly resurfaced skin is more sensitive to UV, and sun exposure during recovery can compromise results and increase pigment risk. A vacation involving significant sun exposure is not the right time to be in the middle of a resurfacing recovery.

The plan accounts for sun exposure, recovery, and the timing of any treatment relative to travel. Sun protection is part of resurfacing — not an optional add-on.

The question assumes a single finish line. In resurfacing, visible change, complete healing, and final remodeling are different endpoints on different timelines. A more intensive treatment may show more visible surface change sooner, but the final remodeling — collagen response, settling, pigment normalization — develops over weeks to months.

Faster is not the same as better, and faster is not the same as complete. The timeline depends on the concern, the intensity, and the individual.

A more intensive ablative procedure may be selected when a greater magnitude of resurfacing is appropriate. That does not mean it is automatically better for every concern or patient. A dramatic result is only valuable if the concern warranted that magnitude of change.

A surface pigment concern treated with full-field ablation may show dramatic change — and unnecessary recovery and risk. A mild texture concern treated with a non-ablative series may show subtle, cumulative improvement that is exactly right. Dramatic is not the goal. Appropriate is the goal.

ULTRA should not be marketed as CO₂ without CO₂ downtime. They are different technologies with different tissue interactions. The appropriate endpoint for ULTRA should be based on the concern ULTRA is designed to address — not on trying to make ULTRA impersonate CO₂.

If a concern genuinely warrants the magnitude of change that ablative resurfacing provides, that is the conversation to have. If a concern is appropriate for non-ablative fractional resurfacing, ULTRA may be the right tool. Forcing one to imitate the other is not good medicine.

There is no responsible universal equation such as three ULTRA treatments equal one CO₂ treatment. They are different technologies with different tissue interactions. Attempting to create a conversion formula is medically inaccurate and misleading.

ULTRA builds improvement cumulatively over a series within its mechanism. CO₂ creates a more intensive ablative response in a different mechanism. They are not points on the same line. The right question is which mechanism fits the concern — not how many of one equals one of the other.

The number depends on the concern, the goal, the treatment intensity, and the individual response. JOLA's protocol is goal-dependent — not a fixed package. A consultation determines the plan based on what we are treating and how the skin responds.

For the full treatment-count conversation, read the Complete ULTRA Guide.

CO₂ protocols vary based on treatment intensity, condition, device, goal, previous treatment, and patient. A single intensive fractional treatment may produce meaningful change for some concerns; others may benefit from more than one session. The plan is built around the goal and the individual response.

CO₂ is not automatically one-and-done, and it is not automatically a series. The number depends on what is being treated and how.

Sometimes a single intensive treatment may produce meaningful change. But there is no universal one-treatment guarantee. Whether one session is enough depends on the concern, the intensity, the scar morphology, the skin, and the goal.

Some concerns respond well to a single more intensive session. Others require a series or a combination approach. The consultation sets the expectation honestly.

There is no universal winner on longevity. Aging continues, sun exposure continues, acne may continue, pigmentation can recur, and skin biology changes. No resurfacing treatment stops time. Maintenance and ongoing skin health are part of any plan.

A more intensive treatment may produce a more significant change, but it does not freeze the skin in place. A lower-downtime series may maintain improvement with ongoing sessions. Longevity is about the plan, not just the single treatment.

The one-and-done framing is marketing language, not a clinical guarantee. A single intensive CO₂ treatment may produce meaningful change, but maintenance and ongoing aging still matter. The skin continues to age after any treatment.

The question is not whether a treatment is one-and-done. The question is what the long-term plan looks like — maintenance, sun protection, and ongoing skin health — after the initial treatment.

Possibly, depending on the concern and the desired magnitude of change. But ULTRA should not be chosen solely because someone wants to avoid CO₂ recovery if ULTRA does not appropriately match the treatment goal. If the concern genuinely warrants ablative resurfacing, a lower-downtime alternative may underdeliver.

The right approach is to identify the concern first, then determine which technology fits. If ULTRA fits, it is an excellent lower-downtime option. If the concern warrants more intensive resurfacing, avoiding downtime by choosing the wrong tool does not serve the goal.

Not necessarily. Maximum treatment intensity is not the same as optimal treatment selection. A bigger procedure does not automatically mean a better outcome — it may mean more recovery and risk for a concern that did not warrant it.

If the concern genuinely warrants the magnitude of change that ablative resurfacing provides, that conversation is appropriate. But choosing intensity by default — because bigger sounds better — is not prescription-led planning.

Potentially. The consultation reviews when the CO₂ was performed, which device was used, whether it was fractional or full-field, how the skin responded, whether there were pigment changes or scarring, what the remaining concern is, and the current skin health.

There is no invented waiting period. The decision is based on the individual history and the current skin, assessed at consultation.

Potentially. The same consultation-led principle applies. Previous ULTRA history is reviewed — when it was performed, the settings, the response, and the current goals. The decision is individualized, not based on an arbitrary interval.

Previous treatment history is always part of the consultation. It informs — but does not automatically determine — what is appropriate next.

Stacking similar resurfacing treatments without a clinical reason is not automatically beneficial. Sequential resurfacing may be considered in some long-term plans, but there should be a specific reason — a specific concern that each technology addresses at a different time in the plan.

We do not encourage unnecessary stacking. More devices do not equal more results. The plan should be based on the target and the prior response, not on the idea that combining technologies is inherently better.

Fraxel is a fractional laser brand family, not a single wavelength. Some Fraxel technologies are non-ablative; the comparison depends on which Fraxel device and wavelength is being discussed. Do not generalize Fraxel as one thing.

For the full fractional laser comparison, read the ULTRA vs. Fraxel guide.

Morpheus8 is RF microneedling — not a laser. It uses needles to deliver radiofrequency energy. The mechanism, targets, and recovery differ from laser resurfacing. It is not a substitute for either ULTRA or CO₂.

For the full mechanism comparison, read the ULTRA vs. Morpheus8 guide.

Standard microneedling uses mechanical micro-injury — needles without laser energy. It is a different mechanism from laser resurfacing. The comparison depends on the concern and whether mechanical remodeling or laser energy is more appropriate.

For the full surface/structure comparison, read the ULTRA laser vs. microneedling guide.

IPL and BBL are broad-spectrum pulsed-light technologies, not lasers. They are not laser resurfacing. The mechanism, targets, and recovery differ from fractional laser resurfacing.

For the full color study comparison, read the ULTRA laser vs. IPL/BBL guide.

A patient may think they need resurfacing when their primary concern is actually laxity, jowling, jawline definition, or neck firmness. CO₂ and ULTRA belong to resurfacing conversations. XERF belongs to a radiofrequency firmness and laxity conversation. They are not the same job.

Resurfacing changes the skin surface. Tightening addresses structural support. If the dominant concern is loose skin or loss of firmness, a resurfacing laser is not the answer — XERF may be the more appropriate category.

A clean three-way comparison clarifies which category each technology belongs to. The question is not which is best — it is which category fits the concern.

Texture and laxity can coexist. One device does not have to solve every concern. For selected patients, a resurfacing plan plus a firmness plan may be more logical than trying to force one technology to do both.

This is where the depth-study framework matters: identify what is surface, what is depth, and what is structural support. Each may require a different category of treatment. The plan sequences them appropriately rather than stacking them indiscriminately.

For the firmness conversation, explore XERF at JOLA Dallas.

The decision does not begin with the device. It begins with the concern, its depth, the magnitude of change needed, the recovery that is appropriate, and the pigment risk. Only then does the technology question arise.

Every resurfacing plan at JOLA moves through a specification — not a menu. Intensity is prescribed, not chosen for bragging rights.

JOLA's consultation considers the concern, its magnitude, skin texture, pigmentation, scar morphology, wrinkle depth, movement, skin tone, PIH history, previous laser, previous CO₂, previous ULTRA, previous Fraxel, previous microneedling, previous RF microneedling, sun exposure, barrier health, medications where relevant, downtime tolerance, occupation, travel, events, goals, and willingness to complete aftercare.

No single variable determines the plan. The plan emerges from how all of these factors interact for one individual. This is why a consultation is not a formality — it is the prescription.

JOLA may recommend ULTRA for concerns within its cleared indications and its non-ablative fractional mechanism — selected texture, tone, sun-related pigment, fine lines, and post-acne marks — where a lower-downtime, cumulative approach is clinically appropriate and the skin and pigment risk support it.

ULTRA is not the default winner. It is selected when the concern, the depth, and the recovery profile match its mechanism. For the full ULTRA candidacy conversation, read the Complete ULTRA Guide.

A more intensive ablative resurfacing conversation may be appropriate when the concern is significant — advanced photodamage, more pronounced etched lines, certain scar patterns — and the patient's skin, pigment risk, and recovery tolerance support it. This is a consultation-led decision, never a remote prescription.

JOLA's role is to assess whether the concern warrants that intensity and whether the patient is an appropriate candidate. If the concern does not warrant ablative resurfacing, recommending it would not be good medicine. If it does, that conversation happens in consultation with full transparency about recovery and risk.

The point is honesty: the right amount of resurfacing, whether that is lower-downtime or more intensive.

If the dominant concern is jawline laxity, jowls, neck laxity, or firmness rather than surface texture, a resurfacing laser is not the answer. XERF — a radiofrequency skin-tightening technology — belongs to a different category. Resurfacing changes the skin; tightening addresses support.

Good treatment planning includes the option of not this laser. Neither ULTRA nor CO₂ is appropriate for every concern. Vascular redness, active acne, an uncertain pigmented lesion, melasma requiring another strategy, significant tissue descent, scar tethering requiring another approach, a damaged barrier, recent significant sun exposure, or no meaningful treatment indication — these are situations where resurfacing may not be the right conversation.

The most important judgment a provider makes is sometimes that a laser is not the answer. That is not a loss — it is the point of a consultation.

We do not invent pricing. For current ULTRA pricing at JOLA Dallas, contact the practice. For CO₂, we do not invent competitor prices. Cost depends on the device, the provider, the treatment area, whether the treatment is fractional or full-field, anesthesia, aftercare, follow-up, and the number of sessions.

The full plan cost is not always the per-treatment price. A series of lower-downtime sessions and a single more intensive session are different financial conversations. The consultation includes a clear discussion of the total plan, not just one line item.

Treatment cost may include more than the procedure price. Patients may also consider time away from work, social downtime, aftercare products, travel, caregiving responsibilities, and event timing. These are real costs, and they are part of the decision.

This is not a reason to avoid CO₂. It is a reason to be honest about what recovery involves. Recovery has value — it is where the skin remodels. Recovery also has a cost, and that cost should be part of the planning conversation, not a surprise after treatment.

A meaningful comparison requires more than a price. Use this checklist to compare two resurfacing quotes honestly.

ULTRA and CO₂ are both laser technologies, but they are not equivalent. ULTRA — the LaseMD Ultra by Cynosure Lutronic — is a 1927 nm non-ablative fractional thulium laser. CO₂ uses approximately 10,600 nm energy that is strongly absorbed by water and is an ablative resurfacing technology. Fractional does not mean non-ablative; fractional CO₂ is still ablative. Ablation changes the recovery conversation.

Wavelength matters. Water absorption matters for CO₂. Depth matters — different concerns occupy different levels of the skin. Intensity matters, but deeper is not automatically better, more aggressive is not automatically better, and less downtime is not automatically better. Texture and laxity are different. Pigment and scars are different. Acne marks and acne scars are different. Scar morphology matters. Fine lines and dynamic wrinkles differ. Melasma requires caution. Skin tone matters. PIH history matters. Hypopigmentation risk matters. Previous treatments matter.

Healing and social downtime are different. CO₂ should not automatically be described as one-and-done. ULTRA should not be marketed as CO₂ without downtime. Multiple ULTRA treatments should not be mathematically equated to one CO₂ treatment. Maximum intensity is not the goal. XERF belongs to a different firmness and laxity category. Some patients may need resurfacing plus tightening. Some patients may need neither. Cost per treatment is not the entire treatment-plan cost. No universal winner exists.

If you are comparing ULTRA vs. CO₂ laser resurfacing in Dallas, do not begin with which one is stronger. Begin with: What are we trying to change? How deep is the concern? How significant is it? How does my skin heal? What is my pigment risk? How much recovery is appropriate? What magnitude of improvement are we actually trying to create? Then choose the technology.

Sophisticated resurfacing is not about using the most aggressive laser available. It is about prescribing the right amount of treatment.

The depth study is part of JOLA's ULTRA cluster. Each guide owns a specific question. This one owns ULTRA vs. CO₂.